Skip Navigation


Radiation Protection Dosimetry Advance Access originally published online on March 2, 2006
Radiation Protection Dosimetry 2006 118(2):219-226; doi:10.1093/rpd/ncl020
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
118/2/219    most recent
ncl020v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Rijkee, A. G.
Right arrow Articles by Van Der Zee, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rijkee, A. G.
Right arrow Articles by Van Der Zee, W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Assessment of induction of secondary tumours due to various radiotherapy modalities

A. G. Rijkee1,*, J. Zoetelief1, C. P. J. Raaijmakers2, S. C. Van Der Marck3 and W. Van Der Zee

1 Delft University of Technology, Delft
2 University Medical Centre Utrecht, Utrecht
3 Dutch Nuclear Research and consultancy Group, Petten

* Corresponding author: a.g.rijkee{at}tnw.tudelft.nl

One of the objectives of the European Sixth Framework integrated project MAESTRO is to perform an assessment of risk due to various radiotherapy modalities, regarding secondary tumour induction. Initially, the study will focus on cancer of the prostate and the present work represents the first step towards that goal. One of the intended tools, to be used in the assessment, is the Monte Carlo radiation transport code ORANGE. A validation of the ORANGE code's capability to tally dose on a grid superimposed on an existing MCNP geometry is given. Preliminary results on the dose distribution due to conventional radiotherapy treatment of prostate cancer are discussed. Two mathematical models of the patient are proposed and the clinical relevance of the ADAM phantom is investigated. A problem in comparing average doses provided by commercial treatment planning systems and those calculated with Monte Carlo is noticed. The two proposed models are shown to receive a lower dose and average energy deposition than a ‘real’ patient.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.